Learn more about investing in EachDay Health

Our team will get back to you soon to follow up on your inquiry.
Lead Rounds?
EachDay Health
The future of ADHD treatment is digital.
Funding to Date*
Christian Murphy, CEO
“Eachday is a gamified digital therapeutic that reduces ADHD symptoms in adults and adolescents.”
As of 2020, Adult ADHD impacted 9.34% of the global population, and the average U.S. Adult spends $2,228/year on treatment.

There has been a steady rise in Attention-deficit/hyperactivity disorder (ADHD) patients during the last 20 years with adult diagnosis doubling in the last decade. With up to a 91% heritability, and the fact that ADHD can be brought on by environmental factors, this isn’t a problem that’s going to go away… it’s only going to get worse. 

Eachday is a digital health therapeutic company backed by Carnegie Mellon. Composed of UC Berkeley, Carnegie Mellon, Google Highmark and IDEO alumni, Eachday blends technology with medical and academic excellence to deliver evidence-based support for adolescents and adults with ADHD. 

The company is the first to digitize executive function training, delivered via their self-management app that tracks users’ behaviors and interests, such as task completion, cognitive failures,  and self-reported symptoms, to create a personalized “ADHD Profile.” Then, using data and neuroscience, Eachday provides individualized tools and evidence-based techniques to help users better understand their mind, visualize time, and craft routines that reduce the cognitive burden of completing day-to-day activities and help eliminate ADHD symptoms as they occur. Eachday recently completed their first clinical discovery study and is seeking their seed round to conduct clinical trials.